News - Watson Pharmaceuticals, Patents

Filter

Popular Filters

1 to 25 of 33 results

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015

06-03-2013

Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Watson acquires Uteron Pharma; confirms Opana patent challenge

24-01-2013

US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the…

Endo PharmaceuticalsGenericsGrunenthalMergers & AcquisitionsNeurologicalNorth AmericaOpanaPatentsPharmaceuticalUteron PharmaWatson PharmaceuticalsWomen's Health

Patent cliff: one drugmaker's sorrow is another one's joy

20-01-2013

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers…

DilantinGenericsLystedaMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

US Supreme Court agrees to review pay-for-delay generic deals

10-12-2012

The US Supreme Court has agreed to a request by the Federal Trade Commission to look into the practice…

GenericsLegalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

FTC seeks US Supreme Court review in AndroGel "pay-for-delay" case

08-10-2012

At the request of the US Federal Trade Commission, the Solicitor General of the USA petitioned the country's…

Abbott LaboratoriesAndroGelGenericsLegalMen's HealthNorth AmericaPatentsPharmaceuticalSolvayWatson Pharmaceuticals

Watson challenges Pfizer's Pristiq patent

26-06-2012

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

GenericsNeurologicalNorth AmericaPatentsPfizerPharmaceuticalPristiqRegulationWatson Pharmaceuticals

US patent settlements of Xopenex and Lidoderm

30-05-2012

US generics drug major Mylan (Nasdaq: MYL) has entered into a settlement agreement with Sunovion Pharmaceuticals,…

Dainippon Sumitomo PharmaEndo PharmaceuticalsGenericsLidodermMylan LaboratoriesNeurologicalNorth AmericaPatentsRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenex

Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip

20-05-2012

Ireland-headquartered Warner Chilcott (Nasdaq: WCRX) has filed suit against USA-based Watson Pharmaceuticals…

ActavisGenericsGlaxoSmithKlineLegalLo LoestrinMarkets & MarketingNeurologicalNorth AmericaPatentsRegulationReproductiveRequip XLWarner ChilcottWatson Pharmaceuticals

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza

20-04-2012

US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling

05-04-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

AllerganGenericsGenito-urinaryLatisseLegalLumiganOphthalmicsPatentsSanctura XRWatson Pharmaceuticals

Actavis reportedly to be acquired by Watson; debuts generic Zomig

22-03-2012

Icelandic generic drugmaker Actavis is said to be in talks to be acquired by US peer Watson Pharmaceuticals…

ActavisAstraZenecaEuropeGenericsMarkets & MarketingMergers & AcquisitionsNeurologicalPatentsWatson PharmaceuticalsZolmitriptanZomig

Watson confirms Abbott Niaspan patent challenge

19-03-2012

USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

Abbott LaboratoriesCardio-vascularGenericsNiaspanNorth AmericaPatentsWatson Pharmaceuticals

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

1 to 25 of 33 results

Back to top